MODIFICATION
A -- NCI Experimental Therapeutics (NExT) Program Chemical Biology Consortium
- Notice Date
- 9/10/2015
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- S16-001
- Archive Date
- 11/20/2015
- Point of Contact
- SBO Help Desk,
- E-Mail Address
-
NCIOASupport@centeva.com
(NCIOASupport@centeva.com)
- Small Business Set-Aside
- N/A
- Description
- To obtain a copy of this Solicitation No. S16-001, please send an email request to cbcproposals@mail.nih.gov. Proposal Submission Deadline : 5:00 PM (EST) on Thursday, November 5, 2015 For additional information regarding the NExT Program and the CBC, please visit http://next.cancer.gov/ National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research Opportunities-Special Announcements: This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of solicitation for offers. In accordance with FAR 15.201(d), this special notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to: 1) publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR); and 2) increase participation by qualified HUBZone small business, small, small disadvantaged, women-owned small business, veteran-owned small business and service-disabled veteran-owned small business concerns, as applicable. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. for the National Cancer Institute (NCI) under Prime Contract No. HHSN261200800001E, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. The solicitation referenced below is issued by Leidos Biomedical Research, Inc. (Leidos Biomed), a wholly owned subsidiary of Leidos Corporation under its prime contract with the National Cancer Institute (NCI) at Frederick. Leidos Biomed is the Operations and Technical Support Contractor for the operation of the Frederick National Laboratory for Cancer Research (FNLCR) under contract from the National Cancer Institute (NCI). Leidos Biomed is responsible for managing the scientific and administrative aspects of the FNLCR's research endeavors. Title : NCI Experimental Therapeutics (NExT) Program Chemical Biology Consortium Project Background and Objectives : As the Nation's agency responsible for leading the fight against cancer, the NCI launched the Chemical Biology Consortium in 2009 to translate promising discoveries and bring improved therapies to cancer patients. The Chemical Biology Consortium (CBC) is the drug discovery engine of the NExT Program and consists of a network of Centers from academia, government and industry. The Consortium provides access to a broad range of scientific expertise and technical capabilities to support multidisciplinary drug discovery from target validation through clinical candidate selection. This solicitation requests proposals from academic, non-profit or private institutions as well as small biotech companies or Contract Research Organizations (CROs) with expertise in small molecule drug discovery to participate in a Chemical Biology Consortium (CBC). The CBC is a highly collaborative drug discovery consortium designed to integrate all aspects of early stage drug discovery from target validation through candidate selection, leading to the discovery of new molecular entities that the National Cancer Institute (NCI) can sponsor in clinical development. The CBC Centers will provide project teams with the technical expertise and the scientific personnel that are needed to navigate scientific roadblocks and advance projects through the NExT pipeline. As participants on multidisciplinary drug discovery teams, the CBC will enable translation of research findings from leading academic institutions and progression of early stage hit compounds into potent and selective drug candidates for the benefit of patients with cancer. By renewing the CBC Program, the NCI will proceed to identify Centers with scientific excellence and rigor essential for successful drug discovery. Responses are anticipated from academic, non-profit, private institutions, small biotech concerns and service providers (CROs). Interested applicants with technical and scientific expertise to support early drug discovery activities and/or specialized technologies essential for modern drug discovery efforts (e.g. structural biology and fragment based design, biophysical technologies, high content screening, metabolite or epigenetic analyses) are encouraged to apply. For additional information regarding the NExT Program and the CBC, please visit http://next.cancer.gov/ For information concerning other opportunities with the FNLCR, please refer to: http://ncioa.cancer.gov/oa-internet/sbo/welcome.jsp
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/S16-001/listing.html)
- Record
- SN03881222-W 20150912/150911001112-141f97d3178391e0870889731c23c8d1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |